- CEL-SCI Corporation (NYSE:CVM) announces that the Independent Data Monitoring Committee (IDMC) has completed its review for the Company’s pivotal Phase 3 head and neck cancer study of its investigational immunotherapy Multikine (Leukocyte Interleukin, Injection). The study enrolled 928 patients.
- The IDMC saw no evidence of any significant safety questions and recommended continuing the study.
- Multikine (Leukocyte Interleukin, Injection) is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with the Company's future anticipated regulatory submission for approval.
- Shares are up 4% premarket on modest volume.